Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study

The intra vitam diagnosis of prion disease is challenging and a definite diagnosis still requires neuropathological examination in non-familial cases. Magnetic resonance imaging has gained increasing importance in the diagnosis of prion disease. The aim of this study was to compare the usefulness of different magnetic resonance imaging sequences and proton magnetic resonance spectroscopy in the differential diagnosis of patients with rapidly progressive neurological signs compatible with the clinical diagnosis of sporadic prion disease. Twenty-nine consecutive patients with an initial diagnosis of possible or probable sporadic prion disease, on the basis of clinical and electroencephalography features, were recruited. The magnetic resonance protocol included axial fluid-attenuated inversion recovery-T2- and diffusion-weighted images, and proton magnetic resonance spectroscopy of the thalamus, striatum, cerebellum and occipital cortex. Based on the clinical follow-up, genetic studies and neuropathology, the final diagnosis was of prion disease in 14 patients out of 29. The percentage of correctly diagnosed cases was 86% for diffusion-weighted imaging (hyperintensity in the striatum/cerebral cortex), 86% for thalamic N-acetyl-aspartate to creatine ratio (cutoff ≤1.21), 90% for thalamic N-acetyl-aspartate to myo-inositol (mI) ratio (cutoff ≤1.05) and 86% for cerebral spinal fluid 14-3-3 protein. All the prion disease patients had N-acetyl-aspartate to creatine ratios ≤1.21 (100% sensitivity and 100% negative predictive value) and all the non-prion patients had N-acetyl-aspartate to myo-inositol ratios >1.05 (100% specificity and 100% positive predictive value). Univariate logistic regression analysis showed that the combination of thalamic N-acetyl-aspartate to creatine ratio and diffusion-weighted imaging correctly classified 93% of the patients. The combination of thalamic proton magnetic resonance spectroscopy (10 min acquisition duration) and brain diffusion-weighted imaging (2 min acquisition duration) may increase the diagnostic accuracy of the magnetic resonance scan. Both sequences should be routinely included in the clinical work-up of patients with suspected prion disease.

[1]  M. Zeidler,et al.  WHO manual for strengthening diagnosis and surveillance of Creutzfeldt-Jakob disease , 1998 .

[2]  B. Steinhoff,et al.  Diagnostic value of periodic complexes in Creutzfeldt–Jakob disease , 2004, Annals of neurology.

[3]  I. Wilkinson,et al.  Magnetic resonance spectroscopic abnormalities in sporadic and variant Creutzfeldt-Jakob disease. , 2003, Clinical radiology.

[4]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[5]  M. Bahn,et al.  Abnormal diffusion-weighted magnetic resonance images in Creutzfeldt-Jakob disease. , 1999, Archives of neurology.

[6]  N. Venketasubramanian,et al.  Combined diffusion-weighted and spectroscopic MR imaging in Creutzfeldt-Jakob disease. , 2004, Magnetic resonance imaging.

[7]  K. Hess,et al.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease , 2006, Neurology.

[8]  K. Kallenberg,et al.  Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. , 2006, Brain : a journal of neurology.

[9]  P. Goldman-Rakic,et al.  Proton magnetic resonance spectroscopy in Creutzfeldt‐Jakob disease , 1993, Neurology.

[10]  Gavin Giovannoni,et al.  Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. , 2004, Brain : a journal of neurology.

[11]  D. Leibfritz,et al.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. , 1993, Developmental neuroscience.

[12]  J. Collinge,et al.  Neuroimaging findings in human prion disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  P Brown,et al.  Classification of sporadic Creutzfeldt‐Jakob disease based on molecular and phenotypic analysis of 300 subjects , 1999, Annals of neurology.

[14]  R. Castellani,et al.  Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease , 2004, Neurology.

[15]  H. Urbach,et al.  Thalamic involvement in sporadic Creutzfeldt-Jakob disease: a diffusion-weighted MR imaging study. , 2003, AJNR. American journal of neuroradiology.

[16]  A. Colchester,et al.  MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. , 2001, Clinical radiology.

[17]  N. Ayache,et al.  In vivo detection of thalamic gliosis: a pathoradiologic demonstration in familial fatal insomnia. , 2008, Archives of neurology.

[18]  D. MacManus,et al.  Short TE Quantitative Proton Magnetic Resonance Spectroscopy in Variant Creutzfeldt-Jakob Disease , 2006, European Radiology.

[19]  J. Frahm,et al.  In-vivo monitoring of neuronal loss in Creutzfeldt-Jakob disease by proton magnetic resonance spectroscopy , 1991, The Lancet.

[20]  D. MacManus,et al.  Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy , 2006, Neuroradiology.

[21]  C. Jack,et al.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. , 2008, Radiology.

[22]  Pietro Cortelli,et al.  Familial and sporadic fatal insomnia , 2003, The Lancet Neurology.

[23]  Y. Itoyama,et al.  Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt–Jakob disease , 2004, Neurology.

[24]  Horst Urbach,et al.  MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. , 2005, Brain : a journal of neurology.

[25]  B. Miller,et al.  Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. , 2005, AJNR. American journal of neuroradiology.

[26]  U. Heinemann,et al.  Fatal familial insomnia: Clinical features and early identification , 2008, Annals of neurology.

[27]  J. Laplanche,et al.  CSF detection of the 14-3-3 protein in unselected patients with dementia. , 2002, Neurology.

[28]  K. Kallenberg,et al.  Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. , 2006, AJNR. American journal of neuroradiology.

[29]  J Mackenzie,et al.  Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. , 2006, Brain : a journal of neurology.

[30]  H. Urbach,et al.  Radiological assessment of Creutzfeldt-Jakob disease , 2007, European Radiology.

[31]  H. Budka,et al.  Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease , 2000, Neurology.

[32]  Shu G. Chen,et al.  Sporadic and familial CJD: classification and characterisation. , 2003, British medical bulletin.

[33]  I. Zerr,et al.  Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. , 2000, Archives of neurology.

[34]  Dhananjay Ghongade,et al.  Neuroradiology , 2007, Indian Journal of Radiology and Imaging.

[35]  B. Barbiroli,et al.  Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease , 2009, Neurology.

[36]  Peter B Kingsley,et al.  The imaging appearance of Creutzfeldt-Jakob disease caused by the E200K mutation. , 2006, Magnetic resonance imaging.

[37]  H. Kretzschmar,et al.  Molecular subtype-specific clinical diagnosis of prion diseases. , 2007, Veterinary microbiology.